A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2026-01-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, including clinical remission of
guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to
severely active ulcerative colitis (UC).